ELVN
Enliven Therapeutics Inc
Pharmaceuticals
Enliven Therapeutics Inc (ELVN) Stock News
The latest ELVN headlines and market coverage — 1 recent story, updated throughout the day.
- The Motley Fool·Neutral
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?
OrbiMed Advisors, a major shareholder owning over 10% of Enliven Therapeutics, sold 281,408 shares for approximately $12.7 million on June 15, 2026. Despite the company's recent positive Phase III leukemia drug trial data and 95% one-year stock price gain, the insider sale raises questions about whether the hedge fund views the recent rally as a peak opportunity to take profits, though the sale could also reflect routine portfolio rebalancing.